Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-2307
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer ; volume:481 ; number:1 ; day:28 ; month:4 ; year:2022 ; pages:83-92 ; date:7.2022
Virchows Archiv ; 481, Heft 1 (28.4.2022), 83-92, 7.2022
- Urheber
-
Garczyk, Stefan
Degener, Stephan
Bischoff, Felix
Schnitzler, Tician
Salz, Anne
Golz, Reinhard
Buchner, Alexander
Schulz, Gerald B.
Schneider, Ursula
Gaisa, Nadine T.
Knüchel, Ruth
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00428-022-03328-1
- URN
-
urn:nbn:de:101:1-2022081718462159771310
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 11:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Garczyk, Stefan
- Degener, Stephan
- Bischoff, Felix
- Schnitzler, Tician
- Salz, Anne
- Golz, Reinhard
- Buchner, Alexander
- Schulz, Gerald B.
- Schneider, Ursula
- Gaisa, Nadine T.
- Knüchel, Ruth
- SpringerLink (Online service)
Ähnliche Objekte (12)
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder : implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Molecular classification of urothelial bladder carcinoma
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
CD10 expression in urothelial carcinoma of the bladder
Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder : implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Molecular classification of urothelial bladder carcinoma
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
CD10 expression in urothelial carcinoma of the bladder
Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder : implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
Molecular classification of urothelial bladder carcinoma
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study
CD10 expression in urothelial carcinoma of the bladder